Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

464.56 -2.51 (-0.54%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
54 55 Next >
3 Biotech Stocks That Could Make Your Grandchildren Rich
These biotech stocks are poised to generate significant returns to investors due to their high growth potential. 
Via InvestorPlace
Peering Into Vertex Pharmaceuticals's Recent Short Interest
Via Benzinga
Everyone's Talking About Vertex Pharmaceuticals. Is It Time to Buy?
It looks like Vertex's experimental new therapy could become a functional cure for lots of people with diabetes. 
Via The Motley Fool
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Forget Eli Lilly, Buy This Magnificent Biotech Stock Instead
Lilly is a good pick...but this one is better. 
Via The Motley Fool
Investors seeking growth at a reasonable cost should explore NASDAQ:VRTX.
NASDAQ:VRTX is not too expensive for the growth it is showing. 
Via Chartmill
13 Analysts Have This To Say About Vertex Pharmaceuticals
Via Benzinga
Should Quality-Oriented Investors Explore VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX)?
Why NASDAQ:VRTX Stands Out as a Quality Stock. 
Via Chartmill
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
Via Benzinga
3 Top Stocks I'd Buy Today and Hold Forever Without Any Hesitation
Evergreen business models make it easier to hold for the long run. 
Via The Motley Fool
Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC's 'Final Trades'
On CNBC's Halftime Report, Bryn Talkington picked NVIDIA, Jim Lebenthal chose Vertex Pharmaceuticals, Kevin Simpson named ConocoPhillips, and Rob Sechan suggested AbbVie, with all four stocks having... 
Via Benzinga
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Want peace of mind about your investments? Consider these great stocks. 
Via The Motley Fool
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Via Benzinga
This Is What Whales Are Betting On Vertex Pharmaceuticals
Via Benzinga
2 Healthcare Stocks to Buy Hand Over Fist in June
They both have pretty impressive pasts, and their prospects look just as bright. 
Via The Motley Fool
Alphabet To Rally Over 28%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Healthcare And Biotech Investing: Breakthroughs In The Treatment Of Cancer At ASCO
Healthcare stocks underperformed YTD because of weakness in UNH and strength in Technology and Communication Services. 
Via Talk Markets
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
These companies could generate explosive growth over time. 
Via The Motley Fool
Arcturus' Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst
Arcturus Therapeutics shared Phase 1 and Phase 1b trial results for ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis, showing FEV1 improvements and safety . 
Via Benzinga
Analyst Expectations For Vertex Pharmaceuticals's Future
Via Benzinga
While growth is established for NASDAQ:VRTX, the stock's valuation remains reasonable.
NASDAQ:VRTX is showing decent growth, but is still valued reasonably. 
Via Chartmill
Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Large Cap BIopharmaceuticals Overview
As a defensive play healthcare is weighted at about 12% of the S&P 500. 
Via Talk Markets
Topics Stocks
Exposures US Equities
3 No-Brainer Stocks to Buy in June
Now is the time to invest in these great stocks. 
Via The Motley Fool
5 Top Stocks to Buy in June
This medley of growth, value, and income stocks is poised to thrive long-term, even if the stock market sells off this summer. 
Via The Motley Fool
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
Eli Lilly is in a buy zone, while rival Novo Nordisk forged a lower entry. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
A Very Bullish Reversal Produces A Huge Batch Of Actionable Stocks
It is very hard to get excited about what I'm seeing in the stock market because things have not been the way I've wanted them to be. In this video, I want to show you something as we look at a monthly... 
Via Talk Markets
Vertex Stock Recently Hit All-Time High, Leads 8 Top Performers New To IBD Stock Lists
Vertex stock was one of a select group of eight that made it onto IBD top-stocks lists Friday. The big pharma is near its all-time high. 
Via Investor's Business Daily
Should Abbott and DexCom Investors Be Worried About Vertex Pharmaceuticals?
Vertex might not present a clear and present danger to Abbott and DexCom but could present a clear future threat. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
54 55 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.